AU2019202144B2 — Solid forms of {(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino}acetic acid, compositions, and uses thereof
Assigned to Akebia Therapeutics Inc · Expires 2020-10-08 · 6y expired
What this patent protects
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2 carbonyl]amino}acetic acid, compositions comprising thesolid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. 65
USPTO Abstract
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2 carbonyl]amino}acetic acid, compositions comprising thesolid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. 65
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.